Effects of low-level laser therapy on burning mouth syndrome
Valenzuela S, Lopez-Jornet P
Journal of oral rehabilitation · 33 citations
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- University or hospital
- Universidad de Murcia
Based on 1 listed funder(s).
Publication
- Published
- 2016-11-28 · J Oral Rehabil · vol. 44 · issue 2 · pp. 125–132
- Publisher
- Wiley
- Cited
- 61 citations · more than 79% of similar papers · 1.1× the field average
- References
- 23 works
- Access
- Paywalled
- Research areas
- Salivary Gland Disorders and Functions · Laser Applications in Dentistry and Medicine · Temporomandibular Joint Disorders
- Keywords
- Visual analogue scale, Placebo, Medicine, Low level laser therapy, Burning mouth syndrome, Randomized controlled trial, Laser therapy, Placebo group, Anesthesia, Laser, Dentistry, Internal medicine
- MeSH
- humans, burning mouth syndrome, xerostomia, treatment outcome, prospective studies, radiation dosage, adult, aged, aged, 80 and over, middle aged, spain, female, male, lasers, semiconductor, visual analog scale, low-level light therapy
2 authors
From ES
- Sara ValenzuelaHospital General Universitario Morales Meseguer; Universidad de Murcia
- Pía López‐Jornet · correspondingHospital General Universitario Morales Meseguer; Instituto Murciano de Investigación Biosanitaria; Universidad de Murcia
Abstract
To investigate low-level laser therapy (LLLT) applied to treat burning mouth syndrome (BMS). This prospective, comparative, partially blinded, single-centre, clinical trial of GaAlAs Laser, with 815 nm wavelength, included 44 BMS patients divided randomly into three groups: Group I (n = 16): GaAlAs laser 815 nm wavelength, 1 W output power, continuous emissions, 4 s, 4 J and fluence rate 133·3 J cm-2 ; Group II (n = 16): GaAlAs infrared laser, 815 nm wavelength, 1 W output power, continuous emissions, 6 s, 6 J and fluence rate 200 J cm-2 ; Group III (n = 12) placebo group, sham laser. All groups received a weekly dose for 4 weeks. Pain intensity was recorded using a 10-cm visual analogue scale; patients responded to the oral health impact profile (OHIP-14), xerostomia severity test and the hospital anxiety-depression scale (HAD). These assessments were performed at baseline, 2 and 4 weeks. LLLT decreased pain intensity and improved OHIP-14 scores significantly from baseline to 2 weeks in groups I and II compared with the placebo group. No statistically significant differences were found from 2 to 4 weeks. Overall improvements in visual analogue scale (VAS) scores from baseline to the end of treatment were as follows: Group I 15·7%; Group II 15·6%; Group III placebo 7·3%. LLLT application reduces symptoms slightly in BMS patients.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.